UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 

Date of Report (Date of earliest event reported): January 12, 2016 

BRISTOL-MYERS SQUIBB COMPANY 

(Exact Name of Registrant as Specified in its Charter) 

  [DATA_TABLE_REMOVED] 

345 Park Avenue 

New York, NY, 10154 

(Address of Principal Executive Office) 

Registrant’s telephone number, including area code: (212) 546-4000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))    

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))    

Item 8.01. Other Events. 

On January 12, 2016, Bristol Myers Squibb Company will present at the J.P. Morgan Healthcare conference at 9:30 a.m. PST (12:30 p.m. EST). Attached as Exhibit 99.1 is a slide that is being used by Giovanni Caforio, chief executive officer, in that presentation. Materials and an archived edition of the presentation will be available at http://investor.bms.com. 

Item 9.01. Financial Statements and Exhibits. 

(d) Exhibits. 

      99.1     Slide from Presentation of Bristol-Myers Squibb Company dated January 12, 2016.    

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

EXHIBIT INDEX

  Exhibit No.     Description   

  99.1   Slide from Presentation of Bristol-Myers Squibb Company dated January 12, 2016.